Evaluation of CC-95251 Monotherapy and in Combination with Antineoplastic Agents in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes

The primary objective of this study is to evaluate the effect of **CC-95251** when administered alone and in combination with anti-cancer drugs in subjects diagnosed with **Acute Myeloid Leukemia** and **Myelodysplastic Syndromes**. This investigation is clinically relevant as it aims to determine the potential therapeutic benefits and safety profile of CC-95251, which could contribute to improved treatment strategies for these hematological malignancies.

The clinical trial involves a total of **84 participants** diagnosed with **Acute Myeloid Leukemia and Myelodysplastic Syndromes**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. Participants were selected to include a vulnerable population, although specific selection criteria were not disclosed. The general health status of the participants is not specified, and there is no information provided regarding lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided detailed inclusion or exclusion criteria for this trial.

The clinical trial is designed to evaluate the effects of **CC-95251** both as a monotherapy and in combination with other anti-cancer drugs in patients diagnosed with **Acute Myeloid Leukemia** and **Myelodysplastic Syndromes**. This study is structured as a Phase 3, randomized, double-blind, controlled trial, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thereby minimizing bias. The trial is expected to span from January 19, 2022, to September 15, 2029, providing a comprehensive assessment of the treatment's efficacy and safety over an extended period.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This is followed by multiple follow-up visits scheduled at regular intervals to monitor the participants' health status, treatment response, and any adverse effects. The trial will conclude with an end-of-study visit, where final assessments are conducted to gather comprehensive data on the treatment outcomes.

The expected duration of participant involvement in the trial will vary depending on individual response to the treatment and the specific protocol requirements. However, participants are generally expected to remain in the study until its conclusion unless specific conditions necessitate early termination. Such conditions may include significant adverse reactions, withdrawal of consent, or any other medical reasons deemed appropriate by the study investigators. The trial's design and procedures are meticulously crafted to ensure the collection of reliable data while prioritizing participant safety and well-being.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is in Phase 3 and is scheduled to have an estimated recruitment start date of January 19, 2022, with an estimated end date of September 15, 2029. The efficacy of the investigational treatment will be assessed through a structured evaluation process. Although specific primary and secondary endpoints are not detailed, typical Phase 3 trials often involve the use of validated scales, laboratory tests, and patient-reported outcomes to measure efficacy. These assessments are usually conducted at predetermined timepoints throughout the trial, such as at baseline, mid-treatment, and at the end of the treatment period. The data collected will be analyzed to determine the treatment's impact on the disease, with a focus on statistically significant improvements in clinical outcomes. The trial's design and methodology will adhere to rigorous standards to ensure the reliability and validity of the efficacy assessments.